Tandem Diabetes (TNDM) Tops Q2 EPS by 14c

Tandem Diabetes (NASDAQ: TNDM) reported Q2 EPS of $0.06, $0.14 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $172.1 million versus the consensus estimate of $143.63 million.

GUIDANCE:

Tandem Diabetes sees FY2021 revenue of $670-685 million, versus the consensus of $637 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.

You May Also Be Interested In

• Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold
• Qualcomm investor day to detail data center plans Wednesday
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI